Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Glepaglutide

Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease[1][2][3].

Product Specifications

CAS Number

[914009-86-2]

Product Name Alternative

ZP1848

UNSPSC

12352209

Target

GCGR

Type

Peptides

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/glepaglutide.html

Purity

99.53

Solubility

H2O : 50 mg/mL

Smiles

O=C(NCC(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H](CO)C(N[C@@H](CO)C(N[C@@H](CCC(O)=O)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(O)=O)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(N[C@@H](CC3=CNC4=CC=CC=C34)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC5=CNC=N5)N

Molecular Formula

C197H325N53O55

Molecular Weight

4316.08

References & Citations

[1]Naimi RM, et al. a novel long-acting glucagon-like peptide-2 analogue, for patients with short bowel syndrome: a randomised phase 2 trial. Lancet Gastroenterol Hepatol. 2019 May;4 (5) :354-363. |[2]Janssen P, et al. Review article: a comparison of glucagon-like peptides 1 and 2. Aliment Pharmacol Ther. 2013 Jan;37 (1) :18-36. |[3]Jolanta Skarbaliene, et al. ZP1848, a Novel GLP-2 Agonist, Provides a Wide Window of Therapeutic Efficacy in the Experimental Crohn's Disease Model. Gastroenterology, 2011, 140 (5) : S519.

Shipping Conditions

Blue Ice

Storage Conditions

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

Scientific Category

Peptides

Clinical Information

Phase 3

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Human Sulfiredoxin-1, SRXN1 ELISA Kit
MBS9341972-01 48 Well

Human Sulfiredoxin-1, SRXN1 ELISA Kit

Ask
View Details
Human Sulfiredoxin-1, SRXN1 ELISA Kit
MBS9341972-02 96 Well

Human Sulfiredoxin-1, SRXN1 ELISA Kit

Ask
View Details
Human Sulfiredoxin-1, SRXN1 ELISA Kit
MBS9341972-03 5x 96 Well

Human Sulfiredoxin-1, SRXN1 ELISA Kit

Ask
View Details
Human Sulfiredoxin-1, SRXN1 ELISA Kit
MBS9341972-04 10x 96 Well

Human Sulfiredoxin-1, SRXN1 ELISA Kit

Ask
View Details
MIF4GD (NM_020679) Human Tagged ORF Clone
RG207489 10 µg

MIF4GD (NM_020679) Human Tagged ORF Clone

Ask
View Details
Homoveratrylamine
TRC-H669540-10G 10 g

Homoveratrylamine

Ask
View Details